Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

Q3 2024 Earnings Call Transcript November 5, 2024 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.98, expectations were $-1.13. Operator: Good day, everyone, and welcome ...

Teachers and staff at McCourt Middle School, as well as the community at-large, took solidarity to a new level last Thursday, Oct. 31, during their Golden Glow Day ...

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at ...

Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral presentation at the 66th American ...

The New Drug Application (NDA) for revumenib, an oral menin inhibitor, for the treatment of adult and pediatric relapsed or refractory ... patients with R/R mutant nucleophosmin (mNPM1) acute myeloid ...

Only one month away from his third birthday, Dominic Rooney passed away after a two-year battle with cancer nine years ago ...

A new study reveals a modular CAR-T approach that effectively targets heterogeneous antigens in paediatric acute myeloid leukaemia, enhancing treatment success through combinatorial targeting.

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia ... Radon, Even at Levels Below EPA Guideline for Mitigation, Is Linked to Childhood Leukemia ...

Subsequent leukemia was associated with high cumulative doses of epipodophyllotoxins, older age at initial cancer diagnosis, and receipt of hematopoietic stem cell transplant.

REFRaME-P1 is a registration-enabling study evaluating the efficacy and safety of luvelta in infants and children under 12 years of age with CBF/GLIS AML. This will be a global study, with the ...